Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emactuzumab + Atezolizumab in Advanced Solid Tumors
NCT02323191Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2015
- Primary completion
- Aug 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of emactuzumab in triple-negative breast cancer (TNBC), ovarian cancer, bladder cancer and 2 more (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities at 21 days, Maximum Tolerated Dose of Emactuzumab at 21 days and 1 more. Started Jan 2015; status: completed.
02
Drugs
emactuzumab
03
Conditions
triple-negative breast cancer (TNBC)ovarian cancerbladder cancergastric cancer (GC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02323191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323191.